Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. is a development-stage medical technology company developing blood purification and dialysis-like therapies for cardiovascular disease, cancer and severe inflammatory conditions. News about SIGY commonly covers Sigyn Therapy, Sigyn CardioDialysis, ImmunePrep, ChemoPrep and ChemoPure, including product-development presentations, annual-report references and shareholder communications.
Company updates also include capital-structure actions such as its completed reverse stock split and disclosures tied to OTCQB trading, SEC reporting and the development pathway for its therapeutic candidates.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sigyn Therapeutics announces the appointment of Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately. Dr. Marleau, an expert in blood purification technologies, previously served as Chief Technology Officer at Immunicom, leading R&D for cancer treatment candidates. She has significant achievements, including over $6 million in NIH funding and contributions to FDA-cleared Investigational Device Exemptions. Sigyn's lead product, Sigyn Therapy, is designed for pathogen-associated inflammatory disorders, targeting conditions like sepsis and pneumonia. The company's pipeline also includes ChemoPrep and ChemoPure, aimed at enhancing chemotherapy delivery and reducing toxicity. This leadership change could strengthen Sigyn's position in the competitive biotechnology market.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) announced the filing of its Form 10-K annual report for the year ending December 31, 2022. The Company reported a net loss of approximately $2.9 million, consistent with the previous year's loss. In 2022, Sigyn advanced its Sigyn Therapy™ towards clinical studies, targeting pathogen-associated inflammatory disorders like sepsis and renal disease, and expanded its intellectual property and corporate team. Additionally, a cancer treatment system to enhance chemotherapy delivery was initiated. The Company utilized approximately $1.8 million in net cash for operating activities during the year.
Sigyn Therapeutics (OTCQB: SIGY) reported its third quarter results for 2022, showing a net loss of approximately $727,000 ($0.02 per share), slightly higher than the prior year's loss of $666,000. The company has advanced its operations by commencing trading on the OTCQB Venture Exchange and strengthening its Board of Directors. It is also pursuing first-in-human studies for Sigyn Therapy in End-Stage Renal Disease patients. Key developments include a provisional patent application for a cancer treatment system designed to enhance chemotherapy delivery and reduce toxicity.